TTNP Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	10 646.00
Średni wolumen	10 780.00
Kapitalizacja rynkowa	6.48M
EPS	$0 ( 2024-04-02 )
Następna data zysków	( $0 ) 2024-06-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.960
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Mokhtar Firdauz	Sell	0	Common Stock
2024-04-02	Flores Francisco	Sell	0	Common Stock
2024-03-18	Choong Choon Hau	Buy	54 132	Common Stock
2024-03-18	Choong Choon Hau	Sell	0	Convertible Promissory Note
2023-10-25	Natan David	Buy	16 250	Common Stock

INSIDER POWER
-84.85
Last 97 transactions
Buy: 7 283 197 \| Sell: 21 662 130

Titan Pharmaceuticals Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje
NETE	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Titan Pharmaceuticals Inc Finanse

Annual	2023
Przychody:	$184 000
Zysk brutto:	$72 000.00 (39.13 %)
EPS:	$-7.41

FY	2023
Przychody:	$184 000
Zysk brutto:	$72 000.00 (39.13 %)
EPS:	$-7.41

FY	2022
Przychody:	$60 000.00
Zysk brutto:	$-136 000 (-226.67 %)
EPS:	$-15.15

FY	2021
Przychody:	$1.53M
Zysk brutto:	$1.33M (86.96 %)
EPS:	$-0.900

Financial Reports:

No articles found.

Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.